Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Short Interest Up 116.7% in December

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 154,542 shares, an increase of 116.7% from the December 15th total of 71,326 shares. Approximately 2.3% of the shares of the company are sold short. Based on an average trading volume of 86,690 shares, the days-to-cover ratio is currently 1.8 days. Based on an average trading volume of 86,690 shares, the days-to-cover ratio is currently 1.8 days. Approximately 2.3% of the shares of the company are sold short.

Calidi Biotherapeutics Trading Up 1.8%

Shares of CLDI stock traded up $0.02 on Wednesday, hitting $1.12. 16,451 shares of the stock traded hands, compared to its average volume of 72,405. The company has a quick ratio of 2.12, a current ratio of 2.12 and a debt-to-equity ratio of 0.11. Calidi Biotherapeutics has a 52 week low of $1.05 and a 52 week high of $19.20. The firm has a 50 day simple moving average of $1.36 and a two-hundred day simple moving average of $2.72.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($2.21) EPS for the quarter. As a group, equities research analysts anticipate that Calidi Biotherapeutics will post -4.48 EPS for the current year.

Hedge Funds Weigh In On Calidi Biotherapeutics

An institutional investor recently bought a new position in Calidi Biotherapeutics stock. Warberg Asset Management LLC bought a new stake in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,705 shares of the company’s stock, valued at approximately $28,000. Warberg Asset Management LLC owned 0.55% of Calidi Biotherapeutics at the end of the most recent reporting period. 12.53% of the stock is currently owned by hedge funds and other institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.